Ocular Therapeutix Stock Price Target and Analyst Ratings (NASDAQ:OCUL)

Analyst Price Target for OCUL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$24.80

▲ +58.57% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Ocular Therapeutix in the last 3 months. The average price target is $24.80, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 58.57% upside from the last price of $15.64.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Ocular Therapeutix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/30/2019

1 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/28/2020

1 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/27/2020

1 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/26/2020

1 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/24/2020

1 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

1/22/2021

1 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/23/2021

1 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

4/22/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
12/30/2020	JMP Securities	Boost Price Target		$20.00 ➝ $30.00	N/A	i
12/28/2020	HC Wainwright	Downgrade	Buy ➝ Neutral		N/A	i Rating by Y. Chen at HC Wainwright
12/21/2020	Piper Sandler	Boost Price Target		$16.00 ➝ $28.00	Low	i
12/17/2020	Berenberg Bank	Initiated Coverage	Buy	$27.00	Medium	i
11/13/2020	Raymond James	Boost Price Target	Strong-Buy	$15.00 ➝ $25.00	High	i
11/6/2020	HC Wainwright	Boost Price Target	Buy	$13.00 ➝ $14.00	High	i
9/30/2020	HC Wainwright	Reiterated Rating	Buy	$13.00	High	i
8/10/2020	HC Wainwright	Boost Price Target	Buy	$10.00 ➝ $13.00	High	i Rating by Yi Chen at HC Wainwright
7/22/2020	Piper Sandler	Boost Price Target	Overweight	$11.00 ➝ $14.00	Low	i
4/29/2020	HC Wainwright	Reiterated Rating	Positive ➝ Buy	$8.00 ➝ $10.00	High	i Rating by Yi Chen at HC Wainwright
3/17/2020	Jefferies Financial Group	Initiated Coverage	Buy	$8.00	High	i
3/5/2020	Piper Sandler	Reiterated Rating	Overweight	$7.00 ➝ $11.00	High	i
3/4/2020	HC Wainwright	Reiterated Rating	Buy	$8.00	High	i Rating by Yi Chen at HC Wainwright
3/3/2020	Raymond James	Upgrade	Outperform ➝ Strong-Buy		High	i
2/10/2020	Piper Sandler	Boost Price Target		$5.50 ➝ $7.00	Low	i
2/10/2020	HC Wainwright	Reiterated Rating	Buy ➝ Positive	$6.00 ➝ $8.00	Medium	i Rating by Yi Chen at HC Wainwright
11/15/2019	HC Wainwright	Reiterated Rating	Buy	$9.00 ➝ $6.00	High	i Rating by Yi Chen at HC Wainwright
11/12/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$8.00 ➝ $5.00	High	i Rating by Joseph Catanzaro at Piper Jaffray Companies
10/18/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	Low	i Rating by Yi Chen at HC Wainwright
9/25/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	High	i Rating by Yi Chen at HC Wainwright
7/26/2019	Piper Jaffray Companies	Set Price Target	Buy	$8.00	N/A	i Rating by Joseph Catanzaro at Piper Jaffray Companies
7/2/2019	Piper Jaffray Companies	Set Price Target	Buy	$8.00	Low	i Rating by Joseph Catanzaro at Piper Jaffray Companies
7/2/2019	HC Wainwright	Set Price Target	Buy	$9.00	Low	i Rating by Yi Chen at HC Wainwright
6/24/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	High	i Rating by Ram Selvaraju at HC Wainwright
6/21/2019	JMP Securities	Set Price Target	Buy	$9.00	Low	i Rating by Donald Ellis at JMP Securities
5/21/2019	HC Wainwright	Lower Price Target	Buy	$12.00 ➝ $9.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/21/2019	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$11.00 ➝ $5.00	High	i
5/21/2019	Cowen	Downgrade	Outperform ➝ Market Perform	$13.00 ➝ $3.00	High	i
5/20/2019	Piper Jaffray Companies	Lower Price Target	Overweight ➝ Market Perform	$8.00	High	i Rating by Joseph Catanzaro at Piper Jaffray Companies
3/8/2019	Piper Jaffray Companies	Set Price Target	Buy	$14.00	Medium	i Rating by Joseph Catanzaro at Piper Jaffray Companies
3/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$24.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
1/11/2019	HC Wainwright	Set Price Target	Buy	$12.00	Low	i Rating by Ram Selvaraju at HC Wainwright
12/4/2018	HC Wainwright	Reiterated Rating	Buy	$12.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
12/4/2018	Cowen	Reiterated Rating	Buy	$13.00	Medium	i
12/3/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
11/14/2018	Raymond James	Initiated Coverage	Strong-Buy ➝ Strong-Buy	$10.00	High	i
10/11/2018	JMP Securities	Reiterated Rating	Buy	$9.00	High	i Rating by Donald Ellis at JMP Securities
10/10/2018	HC Wainwright	Set Price Target	Buy	$10.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
10/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$22.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
9/6/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight		Low	i
8/20/2018	JMP Securities	Set Price Target	Buy	$9.00	Low	i Rating by Donald Ellis at JMP Securities
8/8/2018	HC Wainwright	Set Price Target	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/7/2018	Cantor Fitzgerald	Set Price Target	Buy	$22.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/20/2018	HC Wainwright	Set Price Target	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
7/19/2018	Cantor Fitzgerald	Set Price Target	Buy	$22.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/2/2018	HC Wainwright	Set Price Target	Buy	$10.00	Low	i Rating by Ram Selvaraju at HC Wainwright
6/21/2018	HC Wainwright	Reiterated Rating	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/9/2018	HC Wainwright	Set Price Target	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$22.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
3/11/2018	BTIG Research	Reiterated Rating	Buy		High	i
3/9/2018	HC Wainwright	Reiterated Rating	Buy	$10.00	Low	i Rating by R. Selvaraju at HC Wainwright
3/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$22.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
1/19/2018	BTIG Research	Upgrade	Neutral ➝ Buy		High	i
11/8/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/23/2017	Guggenheim	Initiated Coverage	Buy	$12.00	N/A	i
9/25/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low	i Rating by Elemer Piros at Cantor Fitzgerald
8/10/2017	BTIG Research	Reiterated Rating	Neutral		Low	i
8/9/2017	HC Wainwright	Reiterated Rating	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/2/2017	HC Wainwright	Set Price Target	Buy	$10.00	High	i Rating by Ram Selvaraju at HC Wainwright
7/26/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$10.00	Low	i
7/17/2017	BTIG Research	Reiterated Rating	Neutral		Low	i
7/14/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$16.00 ➝ $8.00	Low	i
7/12/2017	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $21.00	High	i Rating by Elemer Piros at Cantor Fitzgerald
7/10/2017	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
6/23/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$16.00	High	i
5/15/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$35.00	Low	i Rating by E. Piros at Cantor Fitzgerald
5/15/2017	BTIG Research	Downgrade	Buy ➝ Neutral		Low	i
5/5/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$35.00	Low	i Rating by E. Piros at Cantor Fitzgerald
5/5/2017	BTIG Research	Downgrade	Buy ➝ Neutral		Medium	i
3/21/2017	Cantor Fitzgerald	Reiterated Rating	Overweight		Low	i Rating by E. Piros at Cantor Fitzgerald
3/21/2017	BTIG Research	Reiterated Rating	Buy	$13.00	Low	i Rating by Ling Wang at BTIG Research
3/13/2017	Cowen	Reiterated Rating	Outperform	$60.00	Medium	i
3/11/2017	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Medium	i Rating by Elemer Piros at Cantor Fitzgerald
2/9/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$35.00	N/A	i
1/24/2017	BTIG Research	Reiterated Rating	Buy	$13.00	N/A	i Rating by Ling Wang at BTIG Research
11/15/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$30.00 ➝ $32.00	N/A	i
11/15/2016	Royal Bank of Canada	Boost Price Target	Outperform	$30.00 ➝ $32.00	N/A	i
10/23/2016	BTIG Research	Reiterated Rating	Buy	$18.00	N/A	i Rating by Ling Wang at BTIG Research
10/15/2016	BTIG Research	Reiterated Rating	Buy	$18.00	N/A	i
8/11/2016	JMP Securities	Initiated Coverage	Outperform	$21.00 ➝ $5.84	N/A	i
7/26/2016	BTIG Research	Reiterated Rating	Buy	$18.00	N/A	i
6/7/2016	Morgan Stanley	Reiterated Rating	Overweight	$17.00 ➝ $16.00	N/A	i Rating by Andrew Berens at Morgan Stanley
6/6/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Tyler Van Buren at Cowen Inc
5/12/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by Andrew Berens at Morgan Stanley
4/28/2016	Morgan Stanley	Boost Price Target	Overweight	$15.00 ➝ $17.00	N/A	i Rating by Andrew Berens at Morgan Stanley

(Data available from 4/22/2016 forward)

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Today's Range

Now: $15.64

$15.11

$15.72

50 Day Range

MA: $17.88

$14.78

$20.84

52 Week Range

Now: $15.64

$4.76

$24.30

Volume

4,004 shs

Average Volume

930,798 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocular Therapeutix?

The following Wall Street sell-side analysts have issued stock ratings on Ocular Therapeutix in the last year: Berenberg Bank, HC Wainwright, JMP Securities, Piper Sandler, Raymond James, and Zacks Investment Research.
View the latest analyst ratings for OCUL.

What is the current price target for Ocular Therapeutix?

5 Wall Street analysts have set twelve-month price targets for Ocular Therapeutix in the last year. Their average twelve-month price target is $24.80, suggesting a possible upside of 62.2%. JMP Securities has the highest price target set, predicting OCUL will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $14.00 for Ocular Therapeutix in the next year.
View the latest price targets for OCUL.

What is the current consensus analyst rating for Ocular Therapeutix?

Ocular Therapeutix currently has 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OCUL will outperform the market and that investors should add to their positions of Ocular Therapeutix.
View the latest ratings for OCUL.

What other companies compete with Ocular Therapeutix?

Other companies that are similar to Ocular Therapeutix include Hutchison China MediTech, Sage Therapeutics, Arena Pharmaceuticals, I-Mab, Hypera, Agios Pharmaceuticals, Apellis Pharmaceuticals, Legend Biotech, Turning Point Therapeutics, Nektar Therapeutics, Emergent BioSolutions, Insmed, ACADIA Pharmaceuticals, Atea Pharmaceuticals and Reata Pharmaceuticals.

How do I contact Ocular Therapeutix's investor relations team?

Ocular Therapeutix's physical mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company's listed phone number is (781) 357-4000 and its investor relations email address is [email protected] The official website for Ocular Therapeutix is www.ocutx.com.

NASDAQ:OCUL - Ocular Therapeutix Stock Price Target and Predictions

Analyst Price Target for OCUL

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ocular Therapeutix?

What is the current price target for Ocular Therapeutix?

What is the current consensus analyst rating for Ocular Therapeutix?

What other companies compete with Ocular Therapeutix?

How do I contact Ocular Therapeutix's investor relations team?